As medications like Ozempic and Wegovy continue to reshape obesity treatment, many people are asking the same question: Does Ozempic increase metabolism?
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause patients to lose significant amounts of weight, improve their blood sugar control, and reduce their risk of obesity-related diseases. Those outcomes may sound like proof that the medication has “boosted” their metabolism, but the reality isn’t that simple.
Current research suggests that Ozempic doesn’t directly speed up your metabolism in the way many people imagine. Instead, it improves several aspects of metabolic health, including insulin sensitivity, glucose regulation, and body composition, while helping reduce overall food intake due to decreased appetite. In fact, because resting energy expenditure naturally declines as body weight decreases, many people actually burn fewer calories at rest after losing weight, even as their overall health improves.
Understanding the distinction between metabolism and metabolic health is key to understanding how GLP-1 medications work. In this guide, we’ll explain what metabolism actually is, how it differs from metabolic health, and what current research says about the effects of GLP-1 medications like Ozempic on both.
Evidence Rating—Do GLP-1s Boost Metabolism?
Low/Limited Research
GLP-1 receptor agonist drugs (GLP-1 RAs) are not thought to directly boost metabolism, despite the misconception fueled by rapid weight loss that is common with these medications. However, GLP-1 RAs do have a significant positive effect on metabolic health.
What Is Metabolism?
When people say they have a “fast metabolism” or a “slow metabolism,” what they typically mean is how many calories they burn each day. While energy expenditure is a part of metabolism, the full definition is much more encompassing.
Metabolism is the sum of all chemical reactions that occur inside your body to keep you alive. These processes convert the food you eat into usable energy, build and repair tissues, regulate hormones, support immune function, and power everything from breathing to thinking to exercising.
Your body is constantly using energy, even while you’re asleep. Energy expenditure is categorized into several components:
- Resting metabolic rate (RMR) is the energy your body uses to maintain essential functions like breathing, circulation, brain activity, and organ function. For most adults, RMR accounts for roughly 60% to 75% of total daily energy expenditure1.
- Physical activity includes both structured exercise and non-exercise activity thermogenesis (NEAT), such as walking, fidgeting, or household chores.
- The thermic effect of food (TEF) refers to the calories your body burns digesting, absorbing, and storing nutrients after eating.
Together, these components make up your total daily energy expenditure (TDEE).
Many factors influence metabolism, including age, sex, genetics, hormone levels, body size, and lean body mass. One important point that’s often overlooked is that metabolism naturally adapts to changes in body weight. As someone loses weight, especially a substantial amount of weight, their body requires fewer calories to perform the same basic functions simply because there’s less tissue to maintain. This reduction in energy expenditure is a normal physiological response and doesn’t necessarily indicate that someone’s metabolism has been “damaged.”
RELATED: Do GLP-1s Cause Muscle Loss?
Because of this, improvements in health don’t always correspond with burning more calories, which is where metabolic health comes in.
GGR Recommends — Best Weight Loss Supplements
Rather than relying on fad diets or questionable fat-loss supplements, try these 10 expert-tested and recommended products that can actually help.
Metabolism vs. Metabolic Health
Metabolism refers to how your body uses energy, while metabolic health refers to how well your body’s metabolic systems are functioning.
Someone can have a relatively high metabolic rate yet still have poor metabolic health if they have insulin resistance, elevated blood sugar, abnormal cholesterol levels, chronic inflammation, or excess visceral fat (abdominal fat around the organs).
Conversely, someone with a lower resting metabolic rate may have excellent metabolic health because their body regulates glucose, blood pressure, and lipids efficiently.
Researchers generally define good metabolic health by several markers, including:
- Healthy blood glucose levels
- Good insulin sensitivity
- Normal blood pressure
- Favorable cholesterol and triglyceride levels
- Low levels of chronic systemic inflammation
- Healthy body composition, especially when considering visceral fat
Regardless of metabolic rate, poor metabolic health can contribute to insulin resistance and chronic inflammation, which increase the risk of developing conditions such as type 2 diabetes and cardiovascular disease.
GGR Recommends — Best Weight Loss Programs
Our team of experts has evaluated all of the popular weight loss programs, from Noom to WeightWatchers. See our recommendations:
GLP-1s and Metabolic Health: What the Research Says
If you’ve heard that Ozempic “fixes your metabolism,” that’s a huge oversimplification, but there is a kernel of truth buried underneath it.
GLP-1 receptor agonists don’t appear to directly increase resting metabolic rate, but they do improve several interconnected processes that influence metabolic health. Research consistently shows benefits for blood glucose control, insulin sensitivity, body composition, cardiovascular risk factors, and chronic inflammation2.
“Weight loss is just one visible output of what these drugs actually do, not the mechanism behind them,” explains Dr. Alexander Joshue Acosta Peñafiel, MD, at SonderCare, who says he doesn’t view GLP-1 RAs as weight loss drugs. “GLP-1 agonists are, at their core, a hormone that the body naturally produces but is insufficient in people with obesity, type 2 diabetes, and metabolic dysfunction.”
“You have to look at where GLP-1 receptors actually exist in the body,” Dr. Acosta Peñafiel continues. “They’re not only found in the stomach. They line the pancreas, brain, heart, kidneys and gut and when a GLP-1 drug binds to all of these receptor sites at the same time, weight loss is only one of the effects out of the many.”
Effects on Insulin Sensitivity
One of the most well-established benefits of GLP-1 receptor agonists is improved insulin sensitivity. In fact, the first-ever GLP-1 medication approved by the FDA was Byetta (exenatide) in 2005 for type 2 diabetes.
Insulin is the hormone responsible for helping glucose move from the bloodstream into cells, where it’s used for energy or stored for later use. In people with insulin resistance, cells become less responsive to insulin, forcing the pancreas to produce more of it to keep blood sugar under control.
This process can lead to chronically elevated insulin levels, impaired blood glucose regulation, and eventually type 2 diabetes.
GLP-1 receptor agonists help interrupt this cycle through several mechanisms3. They stimulate insulin secretion when blood glucose is elevated, suppress glucagon (a hormone that stimulates the release of stored sugars into the bloodstream), slow gastric emptying, and reduce appetite. Collectively, these effects improve the body’s ability to regulate glucose while reducing stress on pancreatic beta cells3.
Weight loss also contributes to improved insulin sensitivity. Excess visceral fat is strongly associated with insulin resistance4, and studies consistently show that reductions in abdominal fat improve insulin sensitivity5.
Some evidence also suggests GLP-1 receptor agonists may improve insulin sensitivity independently of weight loss by acting directly on metabolic tissues, though researchers continue to investigate the extent of these effects6.
GGR Recommends — Home Gym Equipment for Weight Loss
We’ve tested all of the best home gym equipment. Here are our top recommendations for strength and cardio equipment for weight loss.
Blood Glucose Regulation
Closely related to insulin sensitivity is blood glucose control. Unlike some diabetes medications, GLP-1 receptor agonists stimulate insulin release only when blood glucose levels are elevated7.
The medications also suppress glucagon secretion after meals, slowing the liver’s production of glucose. Also, delayed gastric emptying causes carbohydrates to enter the bloodstream more gradually, helping reduce post-meal glucose spikes.
Altogether, these effects improve both fasting blood glucose and postprandial (after-meal) blood sugar levels.
Clinical trials and reviews of nearly 40,000 study participants have consistently demonstrated reductions in hemoglobin A1C—a measure of average blood glucose over approximately three months—in people taking GLP-1 receptor agonists for type 2 diabetes. Depending on the medication and dosage, A1C reductions of up to 2% are common8, making GLP-1 drugs among the most effective non-insulin therapies available.
Energy Expenditure and Resting Metabolic Rate
That GLP-1s increase metabolic rate is one of the biggest misconceptions about the drugs. Despite what you may see on social media, there is little evidence that GLP-1 receptor agonists meaningfully increase energy expenditure.
Resting metabolic rate (RMR) reflects the number of calories your body burns simply to maintain basic physiological functions like breathing and blood circulation.
Because GLP-1 medications lead to substantial weight loss, resting metabolic rate typically decreases, not increases, during treatment. This isn’t a harmful side effect or a sign that the metabolism has been “damaged.” A smaller body requires less energy to maintain than a larger one, so this is an expected adaptation to how the drugs act on the body.
Researchers have explored whether GLP-1 signaling might directly influence energy expenditure through actions in the brain or brown adipose tissue9. Animal studies10 have produced some intriguing results, but to date, clinical evidence does not support the idea that medications like semaglutide significantly increase calorie burning at rest11.
Instead, the primary driver of weight loss appears to be reduced energy intake driven by appetite suppression. Simply put, people taking GLP-1 medications generally consume fewer calories because they feel fuller sooner, stay satisfied longer, and experience fewer food cravings.
“The success of GLP-1 medications showed us that body weight is not mainly a behavioral issue,” says Dr. Acosta Peñafiel. “It is a hormonal one. GLP-1 is one of the hormones responsible for signaling fullness to the brain after a meal. That signal is dampened in people with obesity. The brain does not get a strong enough message that the body has had enough food, so hunger persists. What GLP-1 drugs do is bring that signal back to functional levels.”
“When that happens, patients lose weight, but not just that: their relationship to hunger becomes completely different,” he says.
Weight Loss and Adaptive Thermogenesis
Whenever someone loses weight, regardless of how they do it, the body responds by becoming more energy-efficient.
This phenomenon, known as adaptive thermogenesis12, describes a reduction in energy expenditure that’s greater than would be expected based solely on changes in body size. It’s thought to be one of the body’s evolutionary defenses against prolonged calorie restriction.
Adaptive thermogenesis is one reason maintaining significant weight loss can be challenging: As body weight declines, hunger signals often increase while daily calorie requirements decrease.
Importantly, adaptive thermogenesis is not unique to Ozempic or other GLP-1 medications. It occurs after extended calorie restriction, increased physical activity, bariatric surgery, and nearly every successful weight-loss intervention that has been studied.
Current evidence suggests that GLP-1 receptor agonists do not eliminate this physiological adaptation. However, because they continue to suppress appetite and improve satiety, they may help people adhere to the lower calorie intake required to maintain weight loss despite these metabolic changes.
In other words: Rather than increasing metabolism, GLP-1 medications may make the body’s natural metabolic adaptations easier to manage by reducing hunger and food noise.
“We already knew that the gut, the brain and your metabolic health were connected. What GLP1 medications have done is show us how powerful that connection actually is,” says Dr. Supriya Rao, MD, Dipl. ABOM, Dipl. ABLM. “We know that the pathways of hunger, satiety and food reward are all connected and GLP1 medications help prove that obesity is about biology more than it is willpower.”
GGR Recommends — Workouts for Weight Loss
Need help with the exercise component of losing weight? GGR personal trainers have you covered with these guides.
Inflammation
Metabolic health extends beyond body weight and blood sugar. Obesity is often accompanied by chronic, low-grade inflammation, which contributes to insulin resistance, atherosclerosis, fatty liver disease, and increased cardiovascular risk. GLP-1 receptor agonists may help reduce this inflammatory burden.
Clinical studies have reported improvements in inflammatory biomarkers such as C-reactive protein (CRP)13, along with reductions in visceral adipose tissue14, which is strongly linked to systemic inflammation.
GLP-1 therapy also lowers low-grade intestinal inflammation, says Dr. Acosta Peñafiel. “This is the type of inflammation that is present in the gut lining for years without causing any symptoms, but increases the risk of colorectal cancer in the long run,” he says. “Early research has demonstrated a consistent decrease in inflammatory markers throughout the intestinal wall in patients who have been on semaglutide for a long time.”
On top of that, the composition of the gut microbiome changes15 measurably when taking a GLP-1, Dr. Acosta Peñafiel says. “That microbiome effect is an area of study that is ongoing, but in my practice, the downstream improvements in digestion and bloating that patients report are consistent enough that I no longer believe it’s a coincidence.”
Although researchers are still working to understand every mechanism involved, the evidence increasingly suggests that GLP-1 receptor agonists improve metabolic health through multiple complementary pathways16, not just by helping people lose weight.
Taken together, current research points to an important conclusion: Ozempic doesn’t appear to “speed up” metabolism, but it does improve many of the biological systems that determine long-term metabolic health.
GGR Recommends — Everything You Need for Successful Weight Loss
Our guides, all written by registered dietitians, nutrition coaches, and certified personal trainers, contain all the information you need to lose weight and keep it off.
- How to Lose Body Fat
- How Much Cardio To Lose Weight, Explained by Experts
- How to Use Macros for Fat Loss and Muscle Gain
- Weight Loss Statistics: Heavy Truths and Facts
- High-Protein Foods List for Weight Loss—60+ Options
- 13 Expert Tips on Breaking a Weight Loss Plateau
- Transform Your Physique: The Ultimate Body Recomposition Guide
What It Means for You
If you’re taking Ozempic or another GLP-1 receptor agonist, the goal shouldn’t be to “boost” your metabolism. It should be to improve your overall metabolic health.
For people with obesity or type 2 diabetes, that’s exactly what current evidence suggests these medications can do. By improving insulin sensitivity, regulating blood sugar, reducing excess body fat, and lowering cardiovascular risk factors, GLP-1 receptor agonists address many of the underlying processes that contribute to metabolic disease—not just the number on the scale.
That said, the medication is only one piece of the equation.
Lifestyle habits still play a central role in determining long-term health outcomes. Research consistently shows that combining GLP-1 therapy with regular physical activity, a nutritious diet, and adequate sleep produces better results than medication alone17. In particular, resistance training and sufficient protein intake help preserve lean body mass during weight loss, supporting strength, mobility, and healthy aging.
It’s also important to have realistic expectations about how the medication works.
Because weight loss naturally reduces resting energy expenditure, you may burn fewer calories at rest after losing weight than you did before treatment. This doesn’t mean your metabolism has “slowed” in an unhealthy way or that the medication has stopped working. Rather, it’s a normal physiological response to having a smaller body.
Instead of focusing on calorie burn or body weight alone, keep track of other indicators of metabolic health, such as:
- Improved blood glucose or A1C
- Lower blood pressure
- Healthier cholesterol and triglyceride levels
- Reduced waist circumference or visceral fat
- Increased energy for daily activities
- Better physical fitness and strength
- Improved quality of life
These markers provide a better, more complete picture of your health than resting metabolic rate ever could.
If you’re taking a GLP-1 medication for weight management, minimizing muscle loss should also be a priority. Eating enough protein, strength training at least two to three times per week, and staying physically active can help preserve lean tissue while maximizing fat loss and supporting long-term weight maintenance.
RELATED: Are GLP-1s Performance-Enhancing Drugs?
Ultimately, Ozempic isn’t a shortcut to a faster metabolism. It’s a tool that can help improve the body’s metabolic function when used alongside healthy lifestyle habits.
Life After Ozempic: What Happens When You Quit a GLP-1?
“Metabolic rebound” (18) can occur if you take a GLP-1 receptor agonist medication and later discontinue using it. In patients with obesity, that rebound may include weight regain and deterioration of blood sugar control (HbA1c), waist circumference and BMI, and systolic blood pressure.You will also likely notice an increase in appetite and “food noise” if you experienced that prior to starting the medication.
GLP-1s and Metabolic Health: Final Thoughts
Ozempic and other GLP-1 receptor agonists have changed the conversation around obesity treatment, but they’ve also fueled misconceptions about how metabolism works.
Current evidence doesn’t support the idea that Ozempic directly increases resting metabolic rate or “boosts” metabolism. Instead, the medication improves metabolic health by helping regulate blood sugar, enhancing insulin sensitivity, promoting meaningful weight loss, and reducing several risk factors associated with chronic disease.
In other words, the real value of GLP-1 medications isn’t that they make your body burn dramatically more calories. It’s that they help restore healthier metabolic function, making sustainable weight management and improved long-term health more attainable for many people.
GLP-1 and Metabolism FAQs
Does Ozempic increase your metabolism?
Not exactly. Current research does not show that Ozempic significantly increases resting metabolic rate (the number of calories your body burns at rest). Instead, it improves metabolic health by increasing insulin sensitivity, improving blood glucose regulation, reducing appetite, and promoting weight loss. Because people typically lose body mass while taking Ozempic, resting energy expenditure often decreases over time, which is a normal physiological adaptation to weight loss.
Does Ozempic make you burn more calories?
No; weight loss with Ozempic is primarily driven by reduced calorie intake rather than increased calorie expenditure. The medication helps people feel fuller sooner, stay satisfied longer, and experience fewer food cravings, making it easier to maintain a calorie deficit. While some research has explored whether GLP-1 signaling affects energy expenditure, human studies have not found evidence of a clinically meaningful increase in calorie burning.
Can Ozempic improve metabolic health?
Yes; this is one of the medication’s best-supported benefits. Studies have consistently shown that GLP-1 receptor agonists improve blood sugar control, insulin sensitivity, blood pressure, and several cardiovascular risk factors. They also promote significant weight loss and reduce the risk of chronic disease in people with obesity.
Why does metabolism slow down during weight loss?
Whenever you lose weight—whether through diet, exercise, medication, or bariatric surgery—your body requires fewer calories because it has less tissue to maintain. This reduction in resting energy expenditure is a normal biological response and is sometimes accompanied by adaptive thermogenesis, in which energy expenditure decreases slightly more than expected. This doesn’t mean your metabolism is “broken,” but it is one reason that maintaining weight loss can be challenging.
Can you increase your metabolism while taking Ozempic?
While Ozempic itself isn’t likely to raise your resting metabolic rate, healthy lifestyle habits can help support energy expenditure and preserve lean body mass. Resistance training is particularly important because muscle tissue burns more calories at rest than fat tissue. Eating adequate protein, staying physically active throughout the day, getting enough sleep, and maintaining healthy lifestyle habits can all support metabolic health while helping preserve muscle during weight loss.
What are all the GLP-1s?
The most common GLP-1 and GIP receptor agonist drugs include Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), Saxenda (liraglutide), Victoza (liraglutide), Rybelsus (semaglutide). Others include Trulicity (dulaglutide), Byetta (exenatide), and Foundayo (orforglipron). Retatutride19, a triple-agonist medication, is currently in development.
References
- Poehlman ET. A review: exercise and its influence on resting energy metabolism in man. Med Sci Sports Exerc. 1989;21(5):515-525.
- Wang X, Qi M, Yang L, et al. GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection. Front Endocrinol (Lausanne). 2025;16:1614726. Published 2025 Oct 13. doi:10.3389/fendo.2025.1614726
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
- Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81-87. doi:10.1097/MED.0b013e3283514e13
- Sandforth A, von Schwartzenberg R, Arreola E et al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). The Lancet Diabetes & Endocrinology, 2023; 11, 798-810
- Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025;138(6):934-940. doi:10.1016/j.amjmed.2025.01.021
- Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15-27. doi:10.1111/j.1463-1326.2012.01663.x
- Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. Published 2024 Jan 29. doi:10.1136/bmj-2023-076410
- Nogueiras R, Frühbeck G, Lopez M, et al. GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK. Diabetes. 2014;63(10):3346-3358. doi:10.2337/db14-0302
- Krieger JP, Santos da Conceição EP, Sanchez-Watts G, et al. Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. Am J Physiol Regul Integr Comp Physiol. 2018;315(4):R708-R720. doi:10.1152/ajpregu.00068.2018
- Hropot T, Herman R, Janez A, Lezaic L, Jensterle M. Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity. Int J Mol Sci. 2023;24(10):8592. Published 2023 May 11. doi:10.3390/ijms24108592
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34 Suppl 1(0 1):S47-S55. doi:10.1038/ijo.2010.184
- Zoungas, S. et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The Lancet Diabetes & Endocrinology, 14, 7, (544-557), (2026).
- Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2023;18(8):e0289616. Published 2023 Aug 24. doi:10.1371/journal.pone.0289616
- Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. Published 2025 Apr 9. doi:10.3390/nu17081303
- Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. Published 2025 Jul 17. doi:10.1016/j.eclinm.2025.103363
- Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025;90:103680. Published 2025 Nov 28. doi:10.1016/j.eclinm.2025.103680
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. Published 2025 May 30. doi:10.3390/biom15060796
